Mizapin (Mirtazapine)

Mirtazapine, the active ingredient in Mizapin, is a noradrenergic and specific serotonergic antidepressant (NaSSA) presented as an oral tablet for oral use. It is prescribed for the treatment of major depressive disorder in adult patients and works by modulating neurotransmitter activity to improve mood and sleep patterns.

GNH USA supplies Mizapin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product meets EU quality standards and is manufactured under strict Good Manufacturing Practice guidelines.

Mirtazapine, a NaSSA antidepressant, is employed in the therapeutic management of depressive disorders, particularly major depressive disorder, by influencing central neurotransmitter pathways.

- Major depressive disorder: reduces depressive symptoms, improves sleep quality, and can increase appetite and weight, thereby addressing common features of the illness in adult patients.

Mirtazapine may cause a range of adverse reactions, which vary in frequency and severity.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness - Fatigue

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Seizures - Hyponatremia (low sodium levels) - Suicidal thoughts or behavior - Severe skin reactions (e.g., Stevens‑Johnson syndrome) - Cardiac arrhythmias

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential risks. - Pregnancy: safety not established; use only if benefits outweigh risks. - Elderly: increased sensitivity to sedation and falls; start at low dose. - Liver impairment: consider dose adjustment and monitor hepatic function. - Concomitant MAO inhibitors: avoid due to risk of serotonin syndrome. - Suicidal ideation: monitor closely during early treatment. - Store at ambient temperature: keep in the original packaging, protect from moisture and direct sunlight.

Mirtazapine can interact with several drug classes; awareness of interaction severity guides clinical decisions.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis and serotonin syndrome. - Other serotonergic agents (SSRIs, SNRIs, tramadol, linezolid): heightened serotonin toxicity. - CNS depressants (alcohol, benzodiazepines): additive sedation and respiratory depression.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (paroxetine, fluoxetine): may increase mirtazapine plasma levels. - Antihypertensive drugs: possible additive hypotensive effect. - Anticholinergic medications: may exacerbate dry mouth and constipation. - Carbamazepine: may reduce mirtazapine exposure. - Oral contraceptives: potential alteration of hormonal efficacy.